[Adoptive immunotherapy of advanced cancer patients with immune RNA-sensitized lymphocytes].
Tumor cell suspension was prepared from resected tumor tissue of various cancer patients. I-RNA was extracted from lymphoid tissues of rabbits immunized with each tumor cell and CFA. Autologous (in some cases, allogeneic) lymphocytes were prepared with blood cell separator and incubated with I-RNA, then, returned to himself. Twenty five cases of non-curatively resected gastric cancer (group A), 27 cases of stage II-IV of esophageal carcinoma (group B), 21 of lung cancer (group C), 14 of colorectal cancer (group D) and 37 cases with metastatic lesions (group E) were treated with this schedule. Five year cumulative survival rate was 21% in group A, 23% in group B, 46% in group C and 61% in group D, respectively. One case of CR and 5 of PR were recognized in group E. In many cases of the responder, lymphocyte count, ratio of Leu 4+, 3a+ subset in the peripheral bloods increased and skin reaction to autologous tumor cell extract, LAI and LMI became to positive. Interferon activity was also increased in the responder. It was reported on the preliminary study of combination treatment with I-RNA sensitized lymphocytes and IL-2.
Fukushima
M
M
First Department of Surgery, Hirosaki University School of Medicine, Japan.
Takashima
K
K
Tachibana
M
M
Tsushima
T
T
Ogura
Y
Y
Hasegawa
Y
Y
Koie
H
H
D000818:Animals; D006801:Humans; D007116:Immunization, Passive; D007376:Interleukin-2 / Q000494:pharmacology; D008214:Lymphocytes / Q000276:immunology*; D009369:Neoplasms / Q000401:mortality / Q000628:therapy*; D012313:RNA / Q000276:immunology*; D011817:Rabbits; D015996:Survival Rate
D007376:Interleukin-2; C013674:RNA, immune; D012313:RNA